conventional therapy, disease-free survival, overall survival) are the

Progression-free survival (PFS) and overall survival (OS).

Both overall survival and event-free survival were analyzed.

Progression- free survival and overall survival of patients were also estimated.

The results also show improvement in disease-free survival.

Disease-free and overall survival were nonsignificantly better in the goserelin group.

Treatment response, survival, and toxicity were retrospectively analyzed.

Survival, clinical response, and toxicity were analyzed retrospectively.

Only HER-2/neu expression was significantly associated with survival.

The long-term survival of localized forms is around 70%.

DTIC has not been shown to improve progression-free or overall survival.

Kaplan-Meier analysis was used to compare unadjusted ESRD-free survival.

There is therefore a need for more effective treatment options that provide substantial improvement in progression-free survival and overall survival.

c Distant recurrence free survival is defined as the first occurrence of distant recurrence or breast cancer death;

Kaplan-Meier analysis was used to compare unadjusted ESRD-free survival.